RNA 5-Methylcytosine Regulators Contribute to Metabolism Heterogeneity and Predict Prognosis in Ovarian Cancer

5-Methylcytosine (m C) is an abundant and highly conserved modification in RNAs. The dysregulation of RNA m C methylation has been reported in cancers, but the regulatory network in ovarian cancer of RNA m C methylation-related genes and its implication in metabolic regulation remain largely unexplo...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cell and developmental biology Vol. 10; p. 807786
Main Authors Xu, Jie, Liu, Xiaoyi, Chen, Yanjie, Wang, Yuya, Liu, Tao, Yi, Ping
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 18.03.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:5-Methylcytosine (m C) is an abundant and highly conserved modification in RNAs. The dysregulation of RNA m C methylation has been reported in cancers, but the regulatory network in ovarian cancer of RNA m C methylation-related genes and its implication in metabolic regulation remain largely unexplored. In this study, RNA-sequencing data and clinical information of 374 ovarian cancer patients were downloaded from The Cancer Genome Atlas database, and a total of 14 RNA m C regulators were included. Through unsupervised consensus clustering, two clusters with different m C modification patterns were identified with distinct survivals. According to enrichment analyses, glycosaminoglycan and collagen metabolism-related pathways were specifically activated in cluster 1, whereas fatty acid metabolism-related pathways were enriched in cluster 2, which had better overall survival (OS). Besides the metabolism heterogeneity, the higher sensitivity to platinum and paclitaxel in cluster 2 can further explain the improved OS. Ultimately, a least absolute shrinkage and selection operator prediction model formed by ALYREF, NOP2, and TET2 toward OS was constructed. In conclusion, distinct m C modification pattern exhibited metabolism heterogeneity, different chemotherapy sensitivity, and consequently survival difference, providing evidence for risk stratification.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Qian Yang, Cedars Sinai Medical Center, United States
Reviewed by: Yubin Xie, Sun Yat-sen University, China
These authors have contributed equally to this work
Edited by: Xiaoxing Li, The First Affiliated Hospital of Sun Yat-sen University, China
This article was submitted to Signaling, a section of the journal Frontiers in Cell and Developmental Biology
ISSN:2296-634X
2296-634X
DOI:10.3389/fcell.2022.807786